Adapting to Climate Change

To the Editor Dr Patz and colleagues’ raised concerns about the adverse health effects of climate change. They reviewed the evidence on the effects to date of the future risks from a changing climate and the opportunities for effective action to reduce risks. Although the authors urged public health preparedness (adaptation) to climate change, there could be limits to the effectiveness of adaptation.

The present global burden of disease from climate change is relatively small, and it is often assumed that human beings’ capacity to adapt has no limits. Despite health being vulnerable to the vagaries of climate, humans have adjusted their behavioral patterns and technologies to adapt to a diverse range of climates. However, projected anthropogenic climate change will pose new challenges that may be beyond existing coping capacities.

Some extreme weather events have increased heat-related illness and deaths. Changes in local temperature and rainfall have altered the distribution of certain disease vectors. Current public health practices, policies, and infrastructure may come under great pressure with the growing risk of maladaptation.

Recent assessments have identified an increased risk of experiencing tipping points, and the corresponding effects have been projected to be potentially catastrophic. Although there is little quantification of the adaptation potential of public health associated with projected rates and magnitudes of climate change, susceptible communities are already facing limits in their capacity to adapt to existing climate variability.

For example, the health of populations on small islands and in resource-poor countries has been shown to be particularly vulnerable as a result of increasing exposure to severe weather conditions. The reason for concern is that as global warming accelerates, increasingly more communities will approach their adaptation limits.

The article by Patz et al demonstrates that responding to and communicating the related health risks involves making decisions in a changing climate with continuing uncertainty about the timing and severity of the effects. Health professionals will need to better understand the risks of doing nothing and the benefits to public health of undertaking appropriate and timely action.

Cunrui Huang, MD, PhD
Roger Street, MS
Cordia Chu, PhD

Author Affiliations: School of Public Health, Sun Yat-sen University, Guangzhou, China (Huang); Environmental Change Institute, University of Oxford, Oxford, England (Street); Centre for Environment and Population Health, Griffith University, Brisbane, Australia (Chu).

Corresponding Author: Cunrui Huang, MD, PhD, School of Public Health, Sun Yat-sen University, 74 Zhongshan Rd, Guangzhou 510080, China (huangcunrui@hotmail.com).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

In Reply We agree with Dr Huang and colleagues that there are limits to human beings’ capacity to adapt to climate change, especially if preventive measures are not at the level of full society, multisector interventions. Climate change is neither a conventional single disease agent or toxic exposure nor an individual behavior that can be changed through medical technology or classic public health interventions. It represents a risk that can undermine societal stability and disrupt life-supporting natural resources.

We agree that large uncertainties exist in the capacity to adapt in the face of climate conditions never experienced in the past. Some unforeseen problems for adaptation were glimpsed during the 2003 European heat wave. Extreme temperatures melted electrical cables. Nuclear power plants struggled to keep reactors cool. Many adaptation measures that rely on technology, such as air conditioning, may not be so dependable as the mercury climbs to unprecedented levels.

We also agree regarding the urgency of actions on climate change. We do not assume that adaptation to climate risks and mitigation of climate-altering greenhouse gas emissions should be a stepwise progression; our article concluded that curbing fossil fuel combustion must occur quickly and at substantial levels. For example, according to the Intergovernmental Panel on Climate Change, to avoid heating the earth more than 2°C, by 2050 global greenhouse gas emissions would need to be 40% to 70% lower than 2010 levels and emission levels near zero by 2100.

Although such policy measures may at first seem unrealistic, our analysis provided quantitative examples of very large health co-benefits from mitigation of greenhouse gases across at least 3 sectors: energy, transportation, and food systems.

Cleaner energy strategies directed at short-lived climate pollutants could avoid about 1 million to 4 million deaths worldwide annually by 2050 by reducing fine particulate pollution. In the United States, monetized human health benefits associated with lower fine particulate air pollution exposures, particularly by reducing coal burning, could offset the cost of low-carbon policies by up to 10-fold. In other words, the value of health dividends could swamp the costs of striving for an energy efficient, low-carbon economy.

Upward trends in noncommunicable diseases throughout the world stem in part from sedentary lifestyles aided by transportation systems designed for automobile-dependent travel and from diets high in animal products and low in vegetables and fruit. So in addition to air quality improvements, there are more opportunities for public health through the adoption of alternative modes of transportation, especially...
those that promote active transport by foot or bicycle, along-
side effective public transportation, and through the promo-
tion of more healthful diets.

In summary, increasing trends in noncommunicable dis-
eases in parallel to increasing rates of fossil fuel–based en-
ergy consumption that are disrupting the earth’s climate pre-
sent daunting risks to civilization. Yet the interdependence of
these challenges affords a golden opportunity to solve both si-
multaneously. Action must not be delayed.

Jonathan A. Patz, MD, MPH
Howard Frumkin, MD, DrPH
Andrew Haines, MBBS, MD

Author Affiliations: Global Health Institute, University of Wisconsin, Madison
(Patz); School of Public Health, University of Washington, Seattle (Frumkin),
Department of Social and Environmental Health Research, London School of
Hygiene and Tropical Medicine, London, England (Haines).

Corresponding Author: Jonathan A. Patz, MD, MPH, Global Health Institute,
University of Wisconsin, 1710 University Ave, Madison, WI 53726 (patz@wisc.
edu).

Conflict of Interest Disclosures: The authors have completed and submitted
the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were
reported.

1. Keller C. Place matters: mortality, space, and urban form in the 2003 Paris

2. Intergovernmental Panel on Climate Change. Climate Change 2014:

3. Shindell D, Kuylenstierna JCI, Vignati E, et al. Simultaneously mitigating
near-term climate change and improving human health and food security. Science.
2012;335(6065):183-189.

4. Thompson FM, Rausch S, Saari RK, Selin NE. A systems approach to
2014;4:917-923.

Goals of Displaying Health Care Prices to Physicians

To the Editor The price of medical care is an essential com-
ponent in the assessment of value. Drs Riggs and DeCamp4 dis-
cussed concerns about the display of price to physicians. The
discussion is confounded when expanded to the goal of in-
forming patients and ensuring fairness.

The key stakeholder in the assessment of the value of
health care services is the patient. The physician’s role as ex-
pert is to recommend the most cost-effective evaluation and
management strategy. The authors’ initial question of which
price is right reflects that perspective.

The goals of price transparency for physicians and pa-
ients differ. The goal of price provision to the physician should
be to inform his or her recommendation of the most cost-
effective tests or procedures. Some medical societies have pro-
vided appropriateness criteria for various tests that incorpo-
rate cost and outcomes. For this use, the indication of an actual
dollar amount is unnecessary; the use of price indicators (eg,
$, $$, $$$) rather than actual prices can provide the aspect of
price relevant to a physician’s decision to recommend a par-
cular test or procedure.

In discussion with a particular patient, however, the ac-
tual charges are pertinent. The authors suggested that if a pa-
ient is less well insured, the display of the price may de-
crease the chance of him or her receiving a test (compared with
an insured patient) and therefore be unfair. This would only
be unfair if the decision is made by the physician alone, rather
than in consultation with the patient.

If the patient declines a recommended aspect of care based
on the price, this may be unfair, but it is an inappropriate criti-
cism of price transparency. Because individuals in the popu-
lation have various levels of wealth and insurance coverage,
the process of shared decision making can only maximize pa-
tient-centered value in the setting of their individual means
and the bills they will confront.

Differential pricing may be unfair, but it reflects the un-
derlying unfairness of the distribution of wealth and insur-
ance coverage within the population; making prices transpar-
ent is not unfair.

Eric K. Hoffer, MD

Author Affiliation: Vascular and Interventional Radiology, Dartmouth-
Hitchcock Medical Center, Lebanon, New Hampshire.

Corresponding Author: Eric K. Hoffer, MD, Department of Radiology,
Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH
03756 (hoffer@hitchcock.org).

Conflict of Interest Disclosures: The author has completed and submitted
the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were
reported.

In Reply We agree with Dr Hoffer that prices are an essential
component in assessing value and in general have no objec-
tion to the use of price displays. Rather, we argued in our View-
point that since different displayed “prices” (eg, hospital list
price vs Medicare fee amount) might differentially affect phy-
sician behavior, it is important to consider how different prices
might operate in practice and weigh the ethical implications of
each.

We also agree that patients are arguably the most impor-
tant stakeholder when assessing value and that physicians
should engage with patients in discussing the out-of-pocket
costs associated with their care.1 However, in some circum-
stances, robust shared decision making may not be possible.
For example, patients in acute care hospitals or intensive care
units may be unable or uninterested in weighing cost trade-
offs. In a recent survey of hospitalized patients, more than 70%
indicated that they preferred to leave medical decision mak-
ing to their physician.2

Uncertainty over the status of patients’ deductibles, co-
insurance, and eventual out-of-pocket responsibilities fur-
ther complicates truly informed shared decision making. Rec-
ognizing that at least some price displays will operate mainly
at the physician level, our intent was to bring attention to the
ethical considerations involved, such as transparency, pro-
tecting patient well-being, and ensuring fairness.

Hoffer makes a novel suggestion that general indicators of
price (eg, displaying $ vs $$ vs $$$) could suffice to inform
value-based decision making. Particularly if small variations
in price (such as displaying $30 vs $40 for a chest radiograph)
do not affect physician behavior, we agree such strategies are
simpler and worth exploring. However, when potential prices